- Home
- PRAX vs EOLS Comparison
PRAX vs EOLS Comparison
Compare PRAX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- EOLS
- Stock Information
- Founded
- PRAX 2015
- EOLS 2012
- Country
- PRAX United States
- EOLS United States
- Employees
- PRAX N/A
- EOLS N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- PRAX Health Care
- EOLS Health Care
- Exchange
- PRAX Nasdaq
- EOLS Nasdaq
- Market Cap
- PRAX N/A
- EOLS 854.0M
- IPO Year
- PRAX 2020
- EOLS 2018
- Fundamental
- Price
- PRAX $37.87
- EOLS $12.03
- Analyst Decision
- PRAX Strong Buy
- EOLS Strong Buy
- Analyst Count
- PRAX 9
- EOLS 4
- Target Price
- PRAX $123.33
- EOLS $24.67
- AVG Volume (30 Days)
- PRAX 478.0K
- EOLS 710.0K
- Earning Date
- PRAX 05-12-2025
- EOLS 03-04-2025
- Dividend Yield
- PRAX N/A
- EOLS N/A
- EPS Growth
- PRAX N/A
- EOLS N/A
- EPS
- PRAX N/A
- EOLS N/A
- Revenue
- PRAX $8,553,000.00
- EOLS $266,274,000.00
- Revenue This Year
- PRAX N/A
- EOLS $34.56
- Revenue Next Year
- PRAX $789.73
- EOLS $32.26
- P/E Ratio
- PRAX N/A
- EOLS N/A
- Revenue Growth
- PRAX 249.53
- EOLS 31.76
- 52 Week Low
- PRAX $30.01
- EOLS $9.25
- 52 Week High
- PRAX $91.83
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- PRAX 35.22
- EOLS 35.16
- Support Level
- PRAX $33.10
- EOLS $11.59
- Resistance Level
- PRAX $39.60
- EOLS $13.66
- Average True Range (ATR)
- PRAX 2.47
- EOLS 0.55
- MACD
- PRAX 1.53
- EOLS -0.15
- Stochastic Oscillator
- PRAX 72.05
- EOLS 21.26
Stock Price Comparison Chart: PRAX vs EOLS
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.